Predictive Toxicology: Stem Cell Characterisation Must Mature

Pharma IQ

In line with this year’s Predictive Toxicology Academy, Pharma IQ held an exclusive interview with Phillip Hewitt, Head of Early Investigative Toxicology at Merck KGaA to find out his thoughts on the new innovations within predictive toxicology and the vital improvements needed to the application of Induced Pluripotent Stem Cells (iPSCs) in drug discovery today. Pharma IQ: Give us a flavour of your work within predictive toxicology and a few trends you are noticing in the market? Philip: &n...
To continue reading this story get free access